Catalpol ameliorates psoriasis-like phenotypes via SIRT1 mediated suppression of NF-κB and MAPKs signaling pathways

Psoriasis is a chronic inflammatory skin disease that affects approximately 2% of worldwide population, and causing long-term troubles to the patients. Therefore, it is urgent to develop safe and effective therapeutic drugs. Catalpol is a natural iridoid glucoside, that has several remarkable pharma...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Aimin, Zhang, Buxin, Zhao, Wei, Tu, Yuanhui, Wang, Qingxing, Li, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806253/
https://www.ncbi.nlm.nih.gov/pubmed/33323018
http://dx.doi.org/10.1080/21655979.2020.1863015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806253/
https://www.ncbi.nlm.nih.gov/pubmed/33323018
http://dx.doi.org/10.1080/21655979.2020.1863015

Ejemplares similares